Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Study H3E-MW- S108 is a multicenter, single arm, open-label Phase 2 study to determine the
response rate of pemetrexed plus cisplatin in patients with Stage IV gastric cancer, not
amenable to curative surgery, or recurrence after prior surgery, who have had no prior
chemotherapy. It was planned to enroll approximately 50 patients who qualified for tumor
response population.